Study M260
Study name | Iosifescu DV 2008 |
Title | Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder |
Overall design | The aim of this study was to assess whether changes in brain bioenergetics measured with phosphorus magnetic resonance spectroscopy (31P MRS) correlate with treatment outcome during augmentation treatment with triiodothyronine (T3) in major depressive disorder (MDD). Subjects meeting DSM-IV criteria for MDD who had previously failed to respond to selective serotonin reuptake inhibitor (SSRI) antidepressant drugs (depression group, n = 19) received open label and prospective augmentation treatment with T3 (50 ug daily added to their existing SSRI) for 4 weeks. 31P MRS spectra were obtained before and after treatment from all MDD subjects and baseline 31P MRS from normal control subjects matched for age and gender (control group, n = 9). Seven MDD subjects (38.9%) were treatment responders (responder group) and 11 were treatment non-responders (non-responder group). For each metabolite, the peak area was normalized by the total phosphorous signal. |
Study Type | Type1; Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 >= 16 |
Sample size | 28 |
Tissue | Central; Brain; Brain; |
Platform | MRS; MRS: 4-T Varian Unity/Inova (Varian, Palo Alto, California) magnetic resonance scanner; |
PMID | |
DOI | |
Citation | Iosifescu DV, Bolo NR, Nierenberg AA, et al. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry 2008;63(12):1127-34. |
Metabolite |
